These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9811074

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
    Puchelle E, Zahm JM.
    Arch Pediatr; 1995 Jul; 2(7):670-3. PubMed ID: 7663658
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis.
    Konstan MW, Stern RC, Doershuk CF.
    J Pediatr; 1994 May; 124(5 Pt 1):689-93. PubMed ID: 8176554
    [Abstract] [Full Text] [Related]

  • 28. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase.
    Brandt T, Breitenstein S, von der Hardt H, Tümmler B.
    Thorax; 1995 Aug; 50(8):880-2. PubMed ID: 7570441
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
    Shah PL, Scott SF, Knight RA, Hodson ME.
    Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
    [Abstract] [Full Text] [Related]

  • 31. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
    Sun F, Tai S, Lim T, Baumann U, King M.
    Can Respir J; 2002 Mar; 9(6):401-6. PubMed ID: 12522485
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile.
    Zahm JM, Galabert C, Chaffin A, Chazalette JP, Grosskopf C, Puchelle E.
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1779-84. PubMed ID: 9620905
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combined use of rheology and portable low-field NMR in cystic fibrosis patients.
    Abrami M, Maschio M, Conese M, Confalonieri M, Gerin F, Dapas B, Farra R, Adrover A, Torelli L, Ruaro B, Grassi G, Grassi M.
    Respir Med; 2021 Jun; 189():106623. PubMed ID: 34624628
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H.
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.